16,833 results match your criteria Hepatology[Journal]


Deliberations more than a cut-off HBsAg value for Nuc cessation: Authors' Reply.

Hepatology 2019 Feb 19. Epub 2019 Feb 19.

Academy of Preventive Medicine, Shandong University, Jinan, China.

We read the comments by Jeng WJ, et al. with great interest and would like to clarify a few issues raised on our systematic review. We didn't include the study of Wang CC AJG 2016 and Tseng CH J Formos Med Assoc 2018 for unavailable relapse data in the setting of different HBsAg levels at the end of treatment (EOT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30573DOI Listing
February 2019
1 Read

No baclofen for alcohol use disorders even more when liver disease is serious!

Hepatology 2019 Feb 19. Epub 2019 Feb 19.

Université de Rennes, Centre Hospitalier Universitaire de Rennes, Inserm, Centre d'Investigation Clinique, 35000, Rennes, France.

Caputo and colleagues wrongly promoted baclofen for patients with end-stage alcoholic liver disease.(1) First, there is no reason to use it. A recent Cochrane review found a negative benefit harm:ratio of baclofen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30575DOI Listing
February 2019

Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures.

Hepatology 2019 Feb 19. Epub 2019 Feb 19.

Department of Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.

There is an urgent need for an easily assessable preoperative test to predict postoperative liver function recovery and thereby determine the optimal time point of liver resection, specifically as current markers are often expensive, time consuming and invasive. Emerging evidence suggests that microRNA (miRNA) signatures represent potent diagnostic, prognostic and treatment response biomarkers for several diseases. Using next-generation sequencing as an unbiased systematic approach 554 miRNAs were detected in preoperative plasma of 21 patients suffering from postoperative liver dysfunction (LD) after liver resection and 27 matched controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30572DOI Listing
February 2019

Are There Upper Limits in Tumor Burden for Down-staging of HCC to Liver Transplant? Analysis of the All-comers Protocol.

Hepatology 2019 Feb 19. Epub 2019 Feb 19.

Medicine, University of California San Francisco, San Francisco, CA, United States.

Patients with hepatocellular carcinoma (HCC) within University of California, San Francisco down-staging (UCSF-DS) criteria (1 lesion >5cm and <8cm; 2-3 lesions each <5cm or 4-5 lesions each <3cm with total tumor diameter <8cm) who achieved successful down-staging (DS) to Milan criteria had similar outcomes after liver transplant (LT) compared to HCC initially meeting Milan criteria. Nevertheless, little is known about the outcome of DS in patients with initial tumor burden exceeding UCSF-DS criteria, defined as "all-comers" (AC). We compared the intention-to-treat outcomes of DS between 74 patients in the AC group and 133 patients in the UCSF-DS group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30570DOI Listing
February 2019

Reply (to LTE HEP-19-0174).

Hepatology 2019 Feb 19. Epub 2019 Feb 19.

University of Bologna, Medicina Interna, Cardioangiologia, Epatologia - Semeiotica Medica, Via Albertoni, 15, Bologna, Italy.

We thank dr Braillon and dr Naudet for their interest in our review article (1). Based on their comments, several aspects need to be clarified and pointed out. First, we addressed a specific patient population presenting alcohol use disorder (AUD) and alcohol-induced chronic liver disease (ALD) in an advanced stage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30574DOI Listing
February 2019

The Intestinal Microbiome, Plasma Metabolome and Liver Transcriptome- A Conspiracy Driving Hepatic Steatosis.

Hepatology 2019 Feb 19. Epub 2019 Feb 19.

Director, NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, CA, 92093-0887.

With chronic overnutrition the storage of triglyceride in numerous cells including hepatocytes seems inevitable, and can be explained by well recognized pathways of lipid metabolism. This seemingly obvious association between chronic overnutrition and hepatocyte steatosis appears to be regulated by an unnervingly complex set of pathways that are not traditionally thought of as metabolic regulators. The study of regulation of steatosis is traditionally approached by hypothesis driven manner which examine the role of an individual molecules and pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30577DOI Listing
February 2019

Depression: An Overlooked Villain in Autoimmune Hepatitis?

Hepatology 2019 Feb 17. Epub 2019 Feb 17.

Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.

We read with great interest the recent article by Wong et al. on the impact of autoimmune hepatitis (AIH) on health-related quality of life (HRQoL). So far, this issue has been vastly neglected in patients with AIH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30568DOI Listing
February 2019

Repair or Prevent - What is the real impact of normothermic machine perfusion in liver transplantation?

Hepatology 2019 Feb 17. Epub 2019 Feb 17.

Department of Surgery & Transplantation, University Hospital Zurich, Switzerland.

We read with great interest the paper by Jassem et al(1), which provides detailed gene expression profiles of human livers during normothermic machine perfusion (NMP), compared to conventional cold storage. Authors should be congratulated to this extensive analysis, which shows for the first time transcriptional changes during any form of reperfusion under normothermic conditions(1). However, we would like to add a few critical comments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30567DOI Listing
February 2019

The yield and safety of screening colonoscopy in patients evaluated for liver transplantation.

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

Department of Gastroenterology and Hepatology, Erasmus MC University Hospital, Rotterdam, Netherlands.

Colorectal cancer screening with colonoscopy is commonly used in candidate patients for liver transplantation. We initiated this study to define the risk-benefit ratio of performing screening colonoscopy in this population. A retrospective observational study of all consecutive patients undergoing colonoscopy during pre-liver transplantation screening between 2004-2017 was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30562DOI Listing
February 2019

Tissue repair in the mouse liver following acute carbon tetrachloride depends on injury-induced Wnt/β-catenin signaling.

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

Institute for Stem Cell Biology and Regenerative Medicine, Department of Developmental Biology, Howard Hughes Medical Institute, Stanford School of Medicine, Stanford, CA, 94305.

In the liver, Wnt/β-catenin signaling is involved in regulating zonation and hepatocyte proliferation during homeostasis. We have examined Wnt gene expression and signaling after injury and we show by in situ hybridization that Wnts are activated by acute carbon tetrachloride (CCl ) toxicity. Following injury, peri-injury hepatocytes become Wnt-responsive, expressing the Wnt target gene Axin2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30563DOI Listing
February 2019

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

Harvard Medical School, Boston, Massachusetts.

Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients with chronic liver disease (CLD). Lusutrombopag, a small-molecule, thrombopoietin (TPO) receptor agonist, was evaluated as a treatment to raise platelet counts (PC) in patients with thrombocytopenia and CLD undergoing invasive procedures. L-PLUS 2 was a global, phase 3, randomized, double-blind, placebo-controlled study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30561DOI Listing
February 2019

Reply to HEP-17-1319.

Authors:
Anna S Lok

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI.

We are disappointed that the Cochrane Group remains unconvinced that sustained virologic response (SVR) is a validated surrogate outcome and that direct-acting antiviral agents (DAAs) have been demonstrated to improve clinical as well as patient-reported outcomes in patients with chronic hepatitis C. Since our commentary in 2017, there have been many more studies supporting the benefits of SVR and DAA therapies, including a decline in patients added to the waiting list for liver transplantation for hepatitis C. We recognize that randomized controlled trials are the gold standards for showing the benefits of new treatments but given the robust evidence from clinical trials and observational studies all over the world, we do not believe that it is ethical to contemplate withholding clinically proven beneficial therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30564DOI Listing
February 2019
1 Read

Soluble fibers improve metabolic syndrome but may cause liver disease and hepatocellular carcinoma.

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY, 10032, USA.

Nearly 25% of the world's population is suffering from non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity and type 2 diabetes. NAFLD may progress to the development of non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (HCC). With efficient medical therapies lacking, modifications of life style and diet are considered the best options for the prevention and treatment of NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30565DOI Listing
February 2019
1 Read

Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?

Authors:
Mindie H Nguyen

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

Department of Medicine, Division of Gastroenterology and Hepatology, 750 Welch Road, Suite 210, Palo Alto, California, United States.

In this article, Dr. Lai discusses the risk of hip fractures in persons with cirrhosis and when diabetes is present, the risk for hip fracture is 2.5 times greater (9. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30560DOI Listing
February 2019
1 Read

Hip fracture risk in patients with cirrhosis: does diabetes mellitus matter?

Hepatology 2019 Feb 14. Epub 2019 Feb 14.

College of Medicine, China Medical University, Taichung, Taiwan.

Insurance reimbursement claims data used in this study were available for public access. Patient identification numbers were scrambled to ensure confidentiality. Patient informed consent was not required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30566DOI Listing
February 2019
1 Read

Hepatic IRF6 alleviates liver steatosis and metabolic disorder by transcriptionally suppressing PPARγ.

Hepatology 2019 Feb 12. Epub 2019 Feb 12.

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.

Nonalcoholic fatty liver disease (NAFLD) has become a worldwide epidemic. A large and growing unmet therapeutic need has inspired numerous studies in the field. Integrating the published genomic data available in the Gene Expression Omnibus with NAFLD samples from rodents, we discovered that interferon regulatory factor 6 (IRF6) is significantly suppressed in high-fat diet (HFD)-induced fatty liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30559DOI Listing
February 2019
1 Read
11.055 Impact Factor

The renaissance of cholemic nephropathy: A likely underestimated cause of renal dysfunction in liver disease.

Hepatology 2019 Feb 11. Epub 2019 Feb 11.

Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Austria.

In this issue of Hepatology, Bräsen and Mederacke et al (1) present an analysis of all kidney biopsies performed at the gastroenterology and hepatology department at Hannover Medical School over a 16-year period. The authors identified 79 patients with both liver disease and impaired renal function, 57% of whom had acute kidney injury (AKI) or AKI overlapping chronic kidney disease (CKD), while 43% had CKD, as defined by the recently updated European clinical practice guidelines. Interestingly, 8 patients were diagnosed with cholemic nephropathy (CN), who all presented as AKI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30558DOI Listing
February 2019
1 Read

Axin1 deletion induced hepatocarcinogenesis requires intact β-Catenin but not Notch cascade in mice.

Hepatology 2019 Feb 8. Epub 2019 Feb 8.

Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, CA, USA.

Inactivating mutations of AXIN1, a negative regulator of the Wnt/β-Catenin cascade, are among the common genetic events in human hepatocellular carcinoma (HCC), affecting around 10% of cases. In the present manuscript, we sought to define the genetic crosstalk between Axin1 mutants and Wnt/β-catenin as well as Notch signaling cascades along hepatocarcinogenesis. We discovered that c-MET activation and AXIN1 mutations occur concomitantly in ~3 to 5% of human HCC samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30556DOI Listing
February 2019
1 Read

Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis.

Hepatology 2019 Feb 8. Epub 2019 Feb 8.

Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

In Japan, bezafibrate (BF) is a second-line agent for primary biliary cholangitis (PBC) that is refractory to ursodeoxycholic acid (UDCA) treatment. From a retrospective cohort (n=873) from the Japan PBC Study Group, we enrolled 118 patients who had received UDCA monotherapy for ≥1 year followed by combination therapy with UDCA+BF for ≥1 year. GLOBE and UK-PBC scores after UDCA monotherapy (that is, immediately before UDCA+BF combination therapy) were compared with those after 1 year of UDCA+BF combination therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30552DOI Listing
February 2019
1 Read

Carbon Tetrachloride (CCl )-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.

Authors:
Priyankar Dey

Hepatology 2019 Feb 8. Epub 2019 Feb 8.

Human Nutrition Program, Department of Human Sciences, The Ohio State University, Columbus, Ohio, USA.

I read with interest the study by Munoz et. al. (1) that showed CCl -associated intestinal dysbiosis and altered immune phenotype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30555DOI Listing
February 2019

Reply to: Carbon Tetrachloride (CCl4)-Induced Classical Liver Cirrhosis Model: Revisiting The Mode Of Action.

Hepatology 2019 Feb 8. Epub 2019 Feb 8.

Universidad de Alcalá, Alcalá de Henares, Spain.

We read with interest the letter by P Dey regarding our article which addresses the role of microbiome in driving intestinal inflammation, barrier disruption and bacterial translocation in CCl -cirrhosis (1). P Dey claims that dysbiosis and inflammation in this model can be attributed, rather than to cirrhosis, to the effects of CCl on the gut microbiome, and that the resultant dysbiosis becomes the major driver of CCl -liver damage. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30554DOI Listing
February 2019

Reply (to LTE HEP-19-0019.

Authors:
Mary Drinane

Hepatology 2019 Feb 8. Epub 2019 Feb 8.

Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr, Lebanon, New Hampshire, US.

The letter by Kamar et al., advancements in our understanding of chronic hepatitis E infection in solid organ transplant patients over time are highlighted. They cite the 2019 publication on the importance of fecal hepatitis E PCR in determining clearance of chronic infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30545DOI Listing
February 2019
1 Read

Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Authors:
Sikarin Upala

Hepatology 2019 Feb 7. Epub 2019 Feb 7.

Department of Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

We read with interest a recent article written by Yan et al. The authors conducted a randomized trial in patients with coexisting type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) to receive liraglutide, sitagliptin, or insulin glargine as add-on to metformin. The authors observed glycemic control and a reduction in body weight, intrahepatic lipid, and visceral adipose tissue in patients who received liraglutide or sitagliptin and then reported these add-on therapies to be novel pharmacotherapeutic therapies in patients with NAFLD and T2DM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30551DOI Listing
February 2019
1 Read

Reply to : "Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus".

Authors:
Jianping Weng

Hepatology 2019 Feb 7. Epub 2019 Feb 7.

Department of Endocrinology of the First Affiliated Hospital Division of Life Sciences of Medicine of USTC, 96, Jinzhai Rd, Hefei, China, 230026.

We sincerely thank Dr. Sikarin Upala for his interest in our article and for sharing his experience in the treatment of nonalcoholic fatty liver disease (NAFLD). NAFLD is prevalent in patients with type 2 diabetes mellitus (T2DM), yet only preliminary evidence are available on the effect of anti-diabetic agents to NAFLD in T2DM patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30553DOI Listing
February 2019

Clinical Remission of Delta-Aminolevulinic Acid Dehydratase Deficiency through Suppression of Erythroid Heme Synthesis.

Hepatology 2019 Feb 6. Epub 2019 Feb 6.

Porphyria Center Rotterdam, Center for lysosomal and metabolic disease, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

We present a case of delta-aminolevulinic acid dehydratase-porphyria (ADP) who was successfully treated by suppressing bone-marrow production of toxic heme precursors. Together with supporting evidence from earlier cases, it is likely ADP has both hepatic and erythroid origins. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30543DOI Listing
February 2019
1 Read
11.055 Impact Factor

Don't blame it on the sunshine, don't blame it on the moonlight, don't blame it on good times, blame it on the sociocultural factors.

Hepatology 2019 Feb 5. Epub 2019 Feb 5.

Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK, NG5 1PB.

In this issue of Hepatology, Ventura-Cots and colleagues present their study arguing that colder weather and fewer sunlight hours increase alcohol consumption and thus cause alcoholic cirrhosis (1). "Causality" is a key concept for this study. A recent review on the topic highlighted two nicely articulated definitions provided by Lilienfeld ('a factor may be defined as a cause of a disease, if the incidence of the disease is diminished when exposure to this factor is likewise diminished') and Pearl ('X is a cause of Y if Y listens to X and decides its value in response to what it hears. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30547DOI Listing
February 2019

Exosomal IFITM2 transmitted to DCs inhibits IFNα pathway activation and blocks anti-HBV efficacy of exogenous IFNα.

Hepatology 2019 Feb 5. Epub 2019 Feb 5.

Division of Infectious Diseases, National Key Laboratory of Biotherapy and colloaborative Innovation Center for Biotherapy, Sichuan University.

The negative regulators in the interferon signaling pathway inhibit intrahepatic immune response, resulting in suboptimal therapeutic response to interferon-α treatment in chronic hepatitis B (CHB) patients. Identifying the key negative factors and elucidating the regulating mechanism are essential for improving anti-HBV efficacy of interferon-α. From the GEO database, we downloaded and analyzed gene expression profiles of CHB patients with different responses to interferon-α (GSE54747), and found that innate immune status was associated with the interferon-α-based therapeutic response in CHB patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30548DOI Listing
February 2019
2 Reads

Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 knockout mice via let-7 microRNA.

Hepatology 2019 Feb 5. Epub 2019 Feb 5.

Research, Central Texas Veterans Health Care System, Temple, TX, USA.

Cholangiopathies are diseases that affect cholangiocytes, the cells lining the biliary tract. Liver stem cells (LSCs) are able to differentiate into all cells of the liver and possibly influence the surrounding liver tissue by secretion of signaling molecules. One way in which cells can interact is through secretion of extracellular vesicles (EVs), which are small membrane-bound vesicles, containing proteins, miRNAs and cytokines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30542DOI Listing
February 2019
1 Read

PROMININ-1 promotes biliary fibrosis associated with biliary atresia.

Hepatology 2019 Feb 5. Epub 2019 Feb 5.

Children's Hospital Los Angeles, Surgery, Los Angeles, CA, USA.

Background: In patients with biliary atresia (BA), the extent of intrahepatic biliary fibrosis negatively correlates with successful surgical bypass of the congenital cholangiopathy as well as subsequent transplant-free survival. We recently linked the expansion of a population of Prominin-1 (Prom1)-expressing hepatic progenitor cells to biliary fibrogenesis. Herein, we hypothesized that Prom1-expressing progenitor cells play a role in BA-associated fibrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30550DOI Listing
February 2019
1 Read

No clear evidence for an effect of sofosbuvir against hepatitis E virus in organ-transplant-patients.

Hepatology 2019 Feb 5. Epub 2019 Feb 5.

Biomedical Research Center, Northwest Minzu University, Lanzhou, China.

Recently, Drinane et al. presented the case of a kidney-pancreas transplant patient with chronic hepatitis E virus (HEV) infection who failed to clear HEV after two courses of ribavirin, and who thereafter eradicated HEV when ribavirin was combined to sofosbuvir. The authors claimed that sofosbuvir has a therapeutic activity against HEV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30546DOI Listing
February 2019
2 Reads

Tumor Microenvironment Regulation by the ER Stress Transmission Mediator GP73.

Hepatology 2019 Feb 5. Epub 2019 Feb 5.

Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, 100850, P.R.China.

The unfolded protein response (UPR) signal in tumor cells activates UPR signaling in neighboring macrophages, which leads to tumor-promoting inflammation by upregulating UPR target genes and proinflammatory cytokines. However, the molecular basis of this endoplasmic reticulum (ER) stress transmission remains largely unclear. Here, we identified the secreted form of GP73, a Golgi-associated protein functional critical for hepatocellular carcinoma (HCC) growth and metastasis, is indispensable for ER stress transmission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30549DOI Listing
February 2019
2 Reads

Aberrant super-enhancer landscape in human hepatocellular carcinoma.

Hepatology 2019 Feb 5. Epub 2019 Feb 5.

State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

Hepatocellular carcinoma (HCC) cells exploit an aberrant transcriptional program to sustain their infinite growth and progression. Emerging evidence indicates that the continuous and robust transcription of oncogenes in cancer cells is often driven by super-enhancers (SEs). In this study, we systematically compared the SE-landscapes between normal liver and HCC cells and revealed that the cis-acting SE-landscape was extensively reprogrammed during liver carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30544DOI Listing
February 2019

Glial Cell Line Derived Neurotrophic Factor Enhances Autophagic Flux in Mouse and Rat Hepatocytes and Protects Against Palmitate Lipotoxicity.

Hepatology 2019 Feb 4. Epub 2019 Feb 4.

Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA.

Glial cell line Derived Neurotrophic Factor (GDNF) is a protein that is required for the development and survival of enteric, sympathetic, and catecholaminergic neurons. We previously reported that GDNF is protective against high fat diet (HFD)-induced hepatic steatosis in mice through suppression of hepatic expression of peroxisome proliferator activated receptor- γ (PPAR-γ) and genes encoding enzymes involved in de novo lipogenesis. We also reported that transgenic overexpression of GDNF in mice prevented the HFD-induced liver accumulation of the autophagy cargo-associated protein p62/sequestosome 1 (p62/SQSTM1) characteristic of impaired autophagy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30541DOI Listing
February 2019
1 Read

Liver expression of a miniATP7B gene results in long-term restoration of copper homeostasis in a Wilson's disease model.

Hepatology 2019 Feb 1. Epub 2019 Feb 1.

Gene Therapy and Regulation of Gene Expression Program, CIMA. FIMA, University of Navarra, Instituto de Investigacion Sanitaria de Navarra, IDISNA. Pamplona, Spain.

Gene therapy with an adeno-associated vector (AAV) serotype 8 encoding the human ATP7B cDNA (AAV8-ATP7B) is able to provide long-term copper metabolism correction in 6-week-old male Wilson's disease (WD) mice. However, the size of the genome (5.2 kb) surpasses the optimal packaging capacity of the vector, which resulted in low-yield production; in addition, further analyses in WD female mice and in animals with a more advanced disease revealed reduced therapeutic efficacy, as compared to younger males. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30535DOI Listing
February 2019

Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of HCV-Viremic Donors into HCV-Negative Recipients.

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Center for Liver Diseases, The University of Chicago Medicine, Chicago, IL, USA.

Background & Aims: Direct-acting antiviral (DAA) therapy has altered the frequency and outcome of liver transplantation for hepatitis C virus (HCV). The high efficacy and tolerability of DAA therapy has also created a rationale for utilizing HCV-viremic (HCV-RNA-positive) donors, including into HCV-negative recipients. We examined trends in the frequency of organ utilization and graft survival in recipients of HCV-viremic donors (HCV-RNA-positive as measured by Nucleic Acid Testing, NAT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30540DOI Listing
January 2019
1 Read

Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis.

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

Recent cross-sectional studies have examined the association between nonalcoholic fatty liver disease (NAFLD) and bone mineral density (BMD) in children or adolescents, but these have produced conflicting results. We performed a systematic review and meta-analysis of these published studies to quantify the magnitude of the association, if any, between NAFLD and BMD. We searched publication databases from January 2000 to September 2018, using predefined keywords to identify relevant observational studies conducted in children or adolescents in which NAFLD was diagnosed either by imaging or by histology, and BMD Z score was measured by dual energy X-ray absorptiometry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30538DOI Listing
January 2019
1 Read

The Synergistic Effect of Albumin on Terlipressin in Acute on Chronic Liver Failure with Acute Kidney Injury.

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Xenorm MedInfo Center, No. 30 Xue Yuan Road, Haidian District, Beijing, China.

We read with great interest, the trial conducted by Arora et al. in which the authors reported superiority of terlipressin over noradrenaline in treating patients with acute on chronic liver failure (ACLF) and acute kidney injury (AKI). In this study, patients receiving terlipressin had better clinical response and survival compared to those receiving noradrenaline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30539DOI Listing
January 2019
1 Read

Prognostic Role of Ammonia in Cirrhotic Patients.

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Liver Failure Group, UCL Institute for Liver and Digestive Health, Division of Medicine, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, UK.

Ammonia is thought to be central to the pathogenesis of hepatic encephalopathy (HE), but its prognostic role in cirrhotic patients with acute decompensation (AD) is unknown. The aims of this study were to determine the relationship between ammonia levels and severity of HE, association with organ dysfunction and short-term mortality. We identified 498 patients from two institutions as part of prospective observational studies in cirrhotic patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30534DOI Listing
January 2019
2 Reads

Predicting Overt Hepatic Encephalopathy for the Population with Cirrhosis.

Authors:
Elliot B Tapper

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Division of Gastroenterology and Hepatology, University of Michigan.

Hepatic encephalopathy (HE) is associated with poor quality of life, sharply increased mortality, repeated hospitalizations, falls, and motor vehicle accidents. HE manifests with a dynamic spectrum of severity. Overt HE is clinically obvious disorientation, even coma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30533DOI Listing
January 2019
1 Read

FBXW5 mediates the ubiquitination of ASK1 and exacerbates nonalcoholic steatohepatitis.

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Inhibition of apoptosis signal-regulating kinase 1 (ASK1) activation has emerged as a promising target for the treatment of nonalcoholic steatohepatitis (NASH). Multiple forms of posttranslational modifications determine the activity of ASK1. In addition to phosphorylation, recent studies revealed that ubiquitination is essential for ASK1 activation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/hep.30537
Publisher Site
http://dx.doi.org/10.1002/hep.30537DOI Listing
January 2019
6 Reads
11.055 Impact Factor

Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation among Asian Chronic Hepatitis B Patients: an Important Addition.

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Academy of Preventive Medicine, Shandong University, Jinan, China.

We appreciate the comments from Wang et al and their efforts to explore the value of hepatitis B surface antigen (HBsAg) at the end of treatment (EOT) in nucleos(t)ide analogues (NAs) cessation. Although we didn't include the article for unavailable clinical relapse data in the setting of different HBsAg levels at EOT, a cumulative incidence of 9.3% for clinical relapse in chronic hepatitis B (CHB) patients with HBsAg < 100 IU/mL at EOT should be a strong support for conclusions in our review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30531DOI Listing
January 2019
2 Reads

The role of hepatitis B surface antigen in nucleos(t)ide analogues cessation among Asian chronic hepatitis B patients: friend or foe?

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Graduate Institute of Clinical Medicine and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taiwan.

We read with great interest the article by Liu et al. They found that hepatitis B surface antigen (HBsAg level) < 100 IU/mL at end-of-treatment (EOT) seemed to be a useful marker to decide when to stop NAs therapy because it was associated with a low incidence (20-30%) of virological or clinical relapse and high probability (20-60%) of HBsAg loss for chronic hepatitis B (CHB) patients. Although this systemic review provided a practical and attainable cessation criterion instead of infinite NAs treatment, several issues deserve discussion and further investigations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30532DOI Listing
January 2019

Reply to (LTE 18-0142.R2).

Hepatology 2019 Jan 31. Epub 2019 Jan 31.

Department of Hepatology, ILBS, India.

We appreciate Shengtao et al. for showing interest in our study. We do agree that albumin can help synergistically the vasoconstrictors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30536DOI Listing
January 2019
11.055 Impact Factor

Keratin 23 is a PPARA-dependent, MYC-amplified oncogene that promotes hepatocyte proliferation.

Hepatology 2019 Jan 29. Epub 2019 Jan 29.

Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Chronic activation of the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARA) promotes MYC-linked hepatocellular carcinoma in mice. Recent studies have shown that MYC can function as an amplifier of transcription where MYC does not act as an 'on-off' switch for gene expression, but rather accelerates transcription rates at active promoters by stimulating transcript elongation. Considering the possibility that MYC may amplify the expression of PPARA target genes to potentiate cell proliferation and liver cancer, gene expression was analyzed from livers of wild-type and hepatocyte-specific Myc knockout mice (Myc ) treated with the PPARA agonist Wy-14643. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30530DOI Listing
January 2019
1 Read
11.055 Impact Factor

Correction.

Authors:
Sergio Anastasi

Hepatology 2019 Feb;69(2):925

Unit of Oncogenomics and Epigenetics, Regina Elena National Cancer Institute, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30502DOI Listing
February 2019

JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.

Hepatology 2019 Jan 28. Epub 2019 Jan 28.

Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium.

The combination of 3 direct-acting antiviral agents (AL-335, odalasvir and simeprevirJNJ-4178 regimen) for 6 or 8 weeks demonstrated good efficacy and safety in a Phase IIa study in chronic hepatitis C virus (HCV) genotype (GT)-1-infected patients without cirrhosis and has now been evaluated in a larger Phase IIb study, OMEGA-1. This multicenter, randomized, open-label study (NCT02765490) enrolled treatment-naïve and interferon (±ribavirin) treatment-experienced patients with HCV GT1, 2, 4, 5, or 6 infection. Patients with HCV GT3 infection and/or liver cirrhosis were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30527DOI Listing
January 2019

An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity.

Hepatology 2019 Jan 28. Epub 2019 Jan 28.

Department of Pathology, Division of Biological Sciences, and Moores Cancer Center, University of California at San Diego, La Jolla, CA, 92093, USA.

Immunotherapy with checkpoint inhibitors for liver cancer, while active in many clinical trials worldwide, may have uncertain outcomes due to the unique immunotolerant microenvironment of the liver. In previous experiments, we unexpectedly identified a robust liver tumor-preventive effect of a synthetic double-stranded RNA (dsRNA) polyinosinic-polycytidylic acid (polyIC) in mice. Herein we further demonstrate that polyIC given at the pre-cancer stage effectively prevented liver tumorigenesis by activating NK cells, macrophages and some T cell subsets; no inhibitory effect was observed on tumor progression if injected after tumor initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30528DOI Listing
January 2019

The BRUCE-ATR signaling axis is required for accurate DNA replication and suppression of liver cancer development.

Hepatology 2019 Jan 28. Epub 2019 Jan 28.

Department of Cancer and Cell Biology.

Replication fork stability during DNA replication is vital for maintenance of genomic stability and suppression of cancer development in mammals. ATR is a master regulatory kinase that activates the replication stress response to overcome replication barriers. While many downstream effectors of ATR have been established, the upstream regulators of ATR and the impact of such regulation on liver cancer remain unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30529DOI Listing
January 2019
11.055 Impact Factor

Alpha-1 antitrypsin deficiency liver disease, mutational homogeneity modulated by epigenetic heterogeneity with links to obesity.

Hepatology 2019 Jan 25. Epub 2019 Jan 25.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.

Alpha-1 Antitrypsin Deficiency (AATD) liver disease is characterized by marked heterogeneity in presentation and progression despite a common underlying gene mutation, strongly suggesting the involvement of other genetic and/or epigenetic modifiers. Variation in clinical phenotype has added to the challenge of detection, diagnosis, and testing of new therapies in AATD patients. We examined the contribution of DNA methylation (5mC) to AATD liver disease heterogeneity since 5mC responds to environmental and genetic cues, and its deregulation is a major driver of liver disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep.30526DOI Listing
January 2019
1 Read